

GLOBAL DIFFERENCES AND SENTIMENTS ABOUT THE DRUG DEVELOPMENT INDUSTRY, ACCORDING TO DRUG DEVELOPERS

Uncovering the differences facing leading drug development companies based on insights from more than 150 biopharma and biotech leaders worldwide

KEY TAKEAWAYS

-  APAC respondents were more likely to embrace innovation
-  European respondents relied more heavily on data science and analytics
-  US/Canadian respondents were slower to adapt to changes in the industry



CHALLENGES

Lack of specialized knowledge presented more of a challenge for APAC respondents than any other region, with a quarter of APAC leaders surveyed reporting it as one of the top challenges facing their organization.

26% of APAC respondents

9% of European respondents

OPPORTUNITIES + INNOVATION

Data Science

Nearly half of European leaders surveyed viewed data science as an industry opportunity.

44% of European respondents

19% of APAC respondents

Two in three European drug developers currently use data science in their trials.

65% of European respondents

45% of US/Canada respondents

Digitalization

European drug development leaders were more likely to use digitalization.

74% of European and APAC respondents

46% of US/Canada respondents

AI

APAC and European drug developers were more optimistic about artificial intelligence.

42% of APAC respondents

30% of European respondents

13% of US/Canada respondents

Wearables

APAC leaders were twice as likely to favor data collection through wearables/connected health devices.

39% of APAC respondents

19% of US/Canada respondents

DCT

Two-thirds of APAC leaders reported that their organizations currently engage in decentralized, digital and remote trials.

68% of APAC respondents

36% of US/Canada respondents

TIMELINE

European leaders surveyed were nearly three times more likely to perceive **no change in the speed of drug development over the past two years than other regions.**

28% of European respondents felt there has been no change in timeline

VS

10% of APAC respondents felt there has been no change in timeline

Half of respondents worldwide reported that that the **average timeline to produce a drug is longer** now than it was two years ago, compared to one-quarter reporting a faster timeline.

48% longer timeline

24% faster timeline

20% no change in timeline

7% unsure

The PPD clinical research business of Thermo Fisher Scientific is a leading global contract research organization focused on delivering life-changing therapies. Check out the rest of PPD's findings about the state of the drug development industry and learn how our experts can partner with you to simplify your next drug development project.